3.35
+0.05(+1.52%)
Currency In USD
| Previous Close | 3.3 |
| Open | 3.32 |
| Day High | 3.53 |
| Day Low | 3.29 |
| 52-Week High | 19.1 |
| 52-Week Low | 2.7 |
| Volume | 505,047 |
| Average Volume | 1.68M |
| Market Cap | 226.42M |
| PE | -2.7 |
| EPS | -1.24 |
| Moving Average 50 Days | 3.63 |
| Moving Average 200 Days | 10.92 |
| Change | 0.05 |
If you invested $1000 in Perspective Therapeutics, Inc. (CATX) 10 years ago, it would be worth $250 as of February 05, 2025 at a share price of $3.35. Whereas If you bought $1000 worth of Perspective Therapeutics, Inc. (CATX) shares 5 years ago, it would be worth $399.76 as of February 05, 2025 at a share price of $3.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium
GlobeNewswire Inc.
Jan 24, 2025 12:00 PM GMT
Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [212Pb]VMT-α-NET[212Pb]VMT-α-NET continued
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025
GlobeNewswire Inc.
Jan 22, 2025 12:00 PM GMT
SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, toda
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 13, 2025 1:00 PM GMT
Anticipates multiple clinical updates in the next 12-18 months, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of one new asset based on its next generation targeted radiopharmaceutical technology p